research, page-2

Thanks @tewantin..!!

Wilson's have an 'upside' valuation of $5.80 p/share..!! (Wow, one could only hope, definitely before 2024 though, I've been here since 2008!!)

"Valuation: Our risk-adjusted Real Options Value model implies a $1.29 target price on a fully diluted basis. Our upside case, or un-risked valuation for CAVATAK, implies a market capitalisation of $1.4B ($5.80/sh) following FDA approval in 2024..."

Analyst Note (Source)

Bring in a 'decent' offer in 2Q18, when we get new results...